Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

Parkinson's related depression hope

  • Comment

The dopamine agonist pramipexole can alleviate depression and improve the motor skills of people with Parkinson’s disease, a study has found.

Research published in the British Medical Journal’s Online First and The Lancet Neurology used a randomised trial to investigate the safety and efficacy of the treatment for depressive symptoms in patients with mild to moderate PD.

It found that pramipexole significantly improved mental health and motor skills when compared with a placebo.

Study leader Paolo Barone from the University of Naples, Italy, said: “These results suggest that specific stimulation of dopaminergic pathways as provided by pramipexole should be considered in the management of patients with PD and clinically significant depressive symptoms.”

He added that the investigation, the first to show the direct benefits of a dopamine agonist in patients with PD, showed the drug had the potential to become an important treatment.

Depression is common in patients with PD, affecting about 35% of sufferers.

  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.

Related Jobs